A cybersecurity risk assessment is a mandatory analytical process defined by ISO 14971 and IEC 62304 that systematically identifies software vulnerabilities, threat vectors, and the probability of adversarial exploitation in a Software as a Medical Device (SaMD). The assessment evaluates the severity of patient harm resulting from a breach of confidentiality, integrity, or availability, forming the basis for the device's risk management file.
Glossary
Cybersecurity Risk Assessment
The systematic process of identifying threats and vulnerabilities in a medical device's software and estimating the potential impact of exploitation.
REGULATORY COMPLIANCE
What is Cybersecurity Risk Assessment?
A cybersecurity risk assessment is the systematic process of identifying threats and vulnerabilities in a medical device's software and estimating the potential impact of exploitation on patient safety and data confidentiality.
The output directly informs the Software Bill of Materials (SBOM) and security control selection required for FDA premarket submissions. By analyzing the attack surface—from API endpoints to data storage—manufacturers establish a defensible security posture, ensuring that residual risk is reduced to an acceptable level before clinical deployment and post-market surveillance.
THREAT MODELING & VULNERABILITY ANALYSIS
Core Components of a SaMD Cybersecurity Risk Assessment
A systematic framework for identifying, categorizing, and mitigating security threats specific to Software as a Medical Device, as mandated by FDA premarket guidance and post-market obligations.
01
Threat Modeling
The foundational process of identifying potential threat actors, attack vectors, and the specific assets they might target within the device ecosystem. This involves decomposing the system architecture to understand data flows across trust boundaries.
- STRIDE Framework: Analyzes Spoofing, Tampering, Repudiation, Information Disclosure, Denial of Service, and Elevation of Privilege.
- Attack Trees: Hierarchical diagrams mapping the steps an adversary would take to achieve a malicious goal.
- Asset Identification: Cataloging protected health information (PHI), algorithmic intellectual property, and safety-critical device functions.
STRIDE
Primary Methodology
03
Vulnerability Scoring & Exploitability Analysis
The quantitative evaluation of identified weaknesses using standardized metrics to prioritize remediation. This moves beyond simple scanning to assess the clinical impact of a cyber event.
- CVSS v3.1: The Common Vulnerability Scoring System calculates a base score (0-10) based on Attack Vector, Complexity, Privileges Required, and User Interaction.
- Rubric for Medical Devices: Adjusts standard CVSS scores by factoring in patient harm potential. A high-severity vulnerability on a life-sustaining device receives an elevated criticality rating.
- Chaining Analysis: Evaluates how multiple low-severity bugs can be combined to form a critical exploit path.
04
Security Control Effectiveness Assessment
The verification that implemented safeguards adequately reduce risk to an acceptable level. This is not just about having controls, but proving they work against the specific threats identified in the model.
- Defense-in-Depth: Layering controls like authenticated firmware updates, secure boot, and runtime application self-protection (RASP).
- Fuzz Testing: Automated injection of malformed or random data into device interfaces to discover memory corruption bugs and input validation failures.
- Penetration Testing: Simulated attacks on the integrated device system to validate the effectiveness of the security architecture in a realistic operational environment.
05
Risk Evaluation & Acceptance Criteria
The final determination of whether the residual risk—the risk remaining after controls are applied—is outweighed by the device's clinical benefits. This requires a cross-functional benefit-risk analysis.
- Risk Matrix: Maps the likelihood of exploitation against the severity of patient harm (e.g., negligible to catastrophic).
- ALARP Principle: Ensuring risks are reduced to a level that is 'As Low As Reasonably Practicable'.
- Traceability Matrix: Links every identified threat to a specific security requirement, a verification test, and a risk control measure to demonstrate a complete safety case to regulators.
06
Post-Market Vulnerability Management Plan
A documented, proactive strategy for continuous monitoring, triage, and patching of vulnerabilities discovered after the device is on the market. This is a critical component of the FDA's Postmarket Management of Cybersecurity in Medical Devices guidance.
- Coordinated Disclosure: A policy for external researchers to safely report bugs.
- Patch SLAs: Time-bound commitments for deploying critical security patches (e.g., within 60 days for critical vulnerabilities).
- Monitoring Sources: Continuous ingestion of threat intelligence from CISA Known Exploited Vulnerabilities catalog, ISACs, and NIST NVD.
REGULATORY COMPLIANCE
Frequently Asked Questions
Critical questions about integrating cybersecurity risk management into the FDA clearance pathway for Software as a Medical Device (SaMD).
A cybersecurity risk assessment is the systematic process of identifying threats and vulnerabilities in a medical device's software architecture and estimating the potential impact of exploitation on patient safety and data confidentiality. It involves evaluating the attack surface, analyzing threat vectors, and quantifying the severity of harm that could result from a successful breach. Unlike general IT risk assessments, this process is explicitly tied to clinical risk, requiring manufacturers to demonstrate how a loss of confidentiality, integrity, or availability could lead to diagnostic errors, therapeutic mistreatment, or direct physiological injury. The output directly feeds into the ISO 14971 risk management file required by the FDA.
Enabling Efficiency, Speed & Accuracy
Intelligent Analysis, Decision & Execution
We build AI systems for teams that need search across company data, workflow automation across tools, or AI features inside products and internal software.
Talk to Us
Search across company data
Give teams answers from docs, tickets, runbooks, and product data with sources and permissions.
Useful when people spend too long searching or get different answers from different systems.
Enterprise searchRAGPermissions
Read more
Automate internal workflows
Use AI to route work, draft outputs, trigger actions, and keep approvals and logs in place.
Useful when repetitive work moves across multiple tools and teams.
AI agentsWorkflow automationGovernance
Read more
Add AI to products and internal tools
Build assistants, guided actions, or decision support into the software your team or customers already use.
Useful when AI needs to be part of the product, not a separate tool.
AI integrationDecision supportModel routing
Read more
About the author
Prasad Kumkar
CEO & MD, Inference Systems
Prasad Kumkar is the CEO & MD of Inference Systems and writes about AI systems architecture, LLM infrastructure, model serving, evaluation, and production deployment. Over 5+ years, he has worked across computer vision models, L5 autonomous vehicle systems, and LLM research, with a focus on taking complex AI ideas into real-world engineering systems.
His work and writing cover AI systems, large language models, AI agents, multimodal systems, autonomous systems, inference optimization, RAG, evaluation, and production AI engineering.
LinkedIn
Limited slotsGet a Free AI Consultation
Partnered with leading AI, data, and software stack.
How We Work
Custom AI workflows for your Business
One-fit-all AI don't work for modern businesses. At Inferensys, we aim to understand your business & custom requirements; which we use to define most efficient agentic workflows, the data, and the tools for your business.
01
Review the use case
We understand the task, the users, and where AI can actually help.
Read more02
Pick the right approach
We define what needs search, automation, or product integration.
Read more03
Build the first useful version
We implement the part that proves the value first.
Read more04
Improve from there
We add the checks and visibility needed to keep it useful.
Read moreThe first call is a practical review of your use case and the right next step.
Talk to Us